SRPT
equitynet buyingSarepta Therapeutics Inc · NASDAQ NMS - GLOBAL MARKET
Buy it with play money
Fills at the latest stored close and lands in your paper portfolio
Sign in to buy SRPT with $10,000 of play money and watch it from here.
Sign in to tradePrice, and when Congress traded it
Hollow marks where they traded, filled where the filing went public
Hover a marker to see who traded and what it was worth.
If you had bought it yourself
Paid at that day's close, held ever since. No member involved.
Working it out…
Financials
As each period's own 10-K or 10-Q reported it
At the $17.85 close on Oct 9, 2026, against 105.62M shares and the balance sheet at Jun 30, 2026; earnings, sales and cash flow over the four quarters to Jun 30, 2026. A ratio is left out where its denominator is not positive. Fair value is the company's own median P/E, price to sales and price to free cash flow at its last ten fiscal year ends, applied to its trailing figures, the middle of the three: its valuation against its own past, not against its growth or its rivals.
| Line item | FY 2016 Dec 31, 2016 | FY 2017 Dec 31, 2017 | FY 2018 Dec 31, 2018 | FY 2019 Dec 31, 2019 | FY 2020 Dec 31, 2020 | FY 2021 Dec 31, 2021 | FY 2022 Dec 31, 2022 | FY 2023 Dec 31, 2023 | FY 2024 Dec 31, 2024 | FY 2025 Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5.4M | $154.6M | $301M | $380.8M | $540.1M | $701.9M | $933M | $1.2B | $1.9B | $2.2B |
| Gross margin | 97.6% | — | — | — | — | — | — | — | — | 98.8% |
| Operating income | -$266.7M | -$171.6M | -$343.6M | -$705.6M | -$564.2M | -$459.7M | -$536.2M | -$267.8M | $218.1M | -$699.8M |
| Operating margin | -4920.3% | -111.0% | -114.1% | -185.3% | -104.5% | -65.5% | -57.5% | -21.5% | 11.5% | -31.8% |
| Net income | -$267.3M | -$50.7M | -$361.9M | -$715.1M | -$554.1M | -$418.8M | -$703.5M | -$536M | $235.2M | -$713.4M |
| Net margin | -4930.2% | -32.8% | -120.2% | -187.8% | -102.6% | -59.7% | -75.4% | -43.1% | 12.4% | -32.5% |
| EPS (diluted) | -$5.49 | -$0.86 | -$5.46 | -$9.71 | -$7.11 | -$5.15 | -$8.03 | -$5.80 | $2.34 | -$7.13 |
| Operating cash flow | -$245.8M | -$232M | -$388.7M | -$456.5M | $107.5M | -$443.2M | -$325.3M | -$501M | -$205.8M | -$205.5M |
| Capital spending | $5.3M | $12M | $61.2M | $59.6M | $82.2M | $38.5M | $30.8M | $76.1M | $137M | $102M |
| Free cash flow | -$251.2M | -$244M | -$449.8M | -$516.1M | $25.3M | -$481.7M | -$356.2M | -$577.1M | -$342.7M | -$307.5M |
| Buybacks | — | — | — | — | — | — | — | $0 | $0 | $25M |
| Dividends paid | — | — | — | — | — | — | — | — | — | — |
| Cash | $122.4M | $599.7M | $370.8M | $835.1M | $1.5B | $2.1B | $966.8M | $428.4M | $1.1B | $801.3M |
| Debt | $17.7M | $601.3M | $420.6M | — | — | $563.7M | $0 | $105.5M | $0 | $829M |
| Shareholders' equity | $336.7M | $789.2M | $1B | $818.2M | $761.8M | $928M | $385M | $859.3M | $1.5B | $1.1B |
| Shares outstanding | 54.76M | 64.79M | 71.07M | 75.18M | 79.37M | 87.13M | 87.95M | 93.73M | 96.9M | 104.96M |
Figures come from the company's XBRL filings as the SEC publishes them. Quarters are worked out from year-to-date figures, and a fourth quarter is the year less its first nine months, which is why it has no EPS: per-share figures do not subtract. Earlier years are on today's share basis where a split has happened since. A later restatement is not mixed into a year it was never applied to, so where a 10-K restated the year before — a business sold, say — that year's fourth quarter is left blank rather than worked out across two bases. A dash means the company did not report that line under a standard tag for that period. Every filing on EDGAR.
Short interest
Shares sold short, as brokers report them to FINRA twice a month
| Settlement date | Shares short | Change | Days to cover |
|---|---|---|---|
| Sep 30, 2026 | 22.78M | -10.4% | 8.6 |
| Sep 15, 2026 | 25.43M | +3.3% | 8.0 |
| Aug 31, 2026 | 24.62M | -9.0% | 8.5 |
| Aug 14, 2026 | 27.05M | -1.9% | 9.1 |
| Jul 31, 2026 | 27.57M | -3.2% | 8.8 |
| Jul 15, 2026 | 28.49M | -0.9% | 9.2 |
| Jun 30, 2026 | 28.73M | +14.2% | 5.8 |
| Jun 15, 2026 | 25.17M | +0.2% | 9.1 |
Largest fails to deliver, the last year
53 settlement days with at least $10,000 of shares sold and not delivered
| Settlement date | Shares | Value |
|---|---|---|
| Apr 20, 2026 | 128.95K | $2.8M |
| Apr 24, 2026 | 115.27K | $2.4M |
| Apr 9, 2026 | 49.88K | $1.1M |
| Feb 9, 2026 | 48.28K | $893.2K |
| Dec 22, 2025 | 41.19K | $866.6K |
Short interest is every broker's short position at the settlement date, reported to FINRA and published about a week and a half later; it does not say who is short. Days to cover is the short position over the average day's trading, and the share of the company is against the shares outstanding on its latest filing. A fail to deliver is the balance of shares sold and not delivered by settlement, from the SEC: it can be a short seller who never borrowed the stock, but is as often a late delivery that clears within days.
What they lobby on
Disclosed to the Senate, largest spend first
- SAREPTA THERAPEUTICS, INC.$270K
Health Issues, Science/Technology
1st Quarter (Jan 1 - Mar 31) 2026
- SAREPTA THERAPEUTICS, INC.$220K
Budget/Appropriations, Health Issues, Science/Technology, Trade (domestic/foreign)
2nd Quarter (Apr 1 - June 30) 2026
- MICHAEL BEST STRATEGIES LLC$110K
Health Issues, Medical/Disease Research/Clinical Labs
1st Quarter (Jan 1 - Mar 31) 2026
- TARPLIN, DOWNS & YOUNG, LLC$90K
Budget/Appropriations, Health Issues, Medicare/Medicaid
2nd Quarter (Apr 1 - June 30) 2026
- TARPLIN, DOWNS & YOUNG, LLC$90K
Budget/Appropriations, Health Issues, Medicare/Medicaid
1st Quarter (Jan 1 - Mar 31) 2026
- MICHAEL BEST STRATEGIES LLC$50K
Health Issues, Medical/Disease Research/Clinical Labs
2nd Quarter (Apr 1 - June 30) 2026
More on SRPT
Who traded it
Most active first
| Member | Buys | Sells |
|---|---|---|
| Gilbert CisnerosCA-31 · house | 7 | 2 |
| Josh GottheimerNJ-05 · house | 3 | 2 |
| Dan GoldmanNY-10 · house | 1 | 2 |
Every disclosure
17 in total, newest first
| Member | Amount |
|---|---|
| Gilbert CisnerosCA · housesell | $1K – $15K |
| Josh GottheimerNJ · housebuyjoint | $1K – $15K |
| Josh GottheimerNJ · houseselljoint | $1K – $15K |
| Dan GoldmanNY · housesell | $15K – $50K |
| Josh GottheimerNJ · housebuyjoint | $1K – $15K |
| Dan GoldmanNY · housebuy | $15K – $50K |
| Dan GoldmanNY · housesell | $1K – $15K |
| Josh GottheimerNJ · houseselljoint | $1K – $15K |
| Gilbert CisnerosCA · housebuy | $1K – $15K |
| Gilbert CisnerosCA · housesell | $1K – $15K |
| Josh GottheimerNJ · housebuyjoint | $1K – $15K |
| Gilbert CisnerosCA · housebuy | $1K – $15K |
| Gilbert CisnerosCA · housebuy | $1K – $15K |
| Gilbert CisnerosCA · housebuy | $1K – $15K |
| Gilbert CisnerosCA · housebuy | $1K – $15K |
| Gilbert CisnerosCA · housebuy | $1K – $15K |
| Gilbert CisnerosCA · housebuy | $1K – $15K |
Follow Sarepta Therapeutics Inc (SRPT) by email
New trades in Sarepta Therapeutics Inc (SRPT) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.